|
17-Hydroxysteroid Dehydrogenase Deficiency
|
0.010 |
Biomarker
|
disease |
BEFREE |
Steroid 17β-hydroxysteroid dehydrogenase III (17β-HSD3) deficiency is a rare autosomal recessive disorder that usually presents in patients with a 46,XY karyotype with ambiguous genitalia at birth.
|
25536660 |
2015 |
|
46, XY Disorders of Sex Development
|
0.040 |
AlteredExpression
|
group |
BEFREE |
We investigated the mRNA transcription patterns of 17beta-hydroxysteroid dehydrogenase-isoenzymes type 1, 2, 3, 4, 5, 7, and 10, 5alpha-reductase type 1 and 2 and the androgen receptor in genital skin fibroblasts from foreskin and scrotal skin obtained from healthy males and patients with unclassified 46,XY DSD. mRNA expression was semi-quantified by real-time PCR.
|
18391534 |
2007 |
|
46, XY Disorders of Sex Development
|
0.040 |
GeneticVariation
|
group |
BEFREE |
Screening for mutations in 17β-hydroxysteroid dehydrogenase and androgen receptor in women presenting with partially virilised 46,XY disorders of sex development.
|
25740850 |
2015 |
|
46, XY Disorders of Sex Development
|
0.040 |
GeneticVariation
|
group |
BEFREE |
Deficiency of 17β-hydroxysteroid dehydrogenase type3 (17β-HSD3) isoenzyme which catalyzes the synthesis of testosterone from Δ4-androstenedione, is the cause of 46, XY disorders of sex development (DSD).
|
25064799 |
2015 |
|
46, XY Disorders of Sex Development
|
0.040 |
GeneticVariation
|
group |
BEFREE |
Biochemical analyses and molecular modeling explain the functional loss of 17β-hydroxysteroid dehydrogenase 3 mutant G133R in three Tunisian patients with 46, XY Disorders of Sex Development.
|
26545797 |
2016 |
|
Adenocarcinoma of colon
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The present study investigated prereceptor estrogen metabolism through steroid sulphatase (STS) and 17β-hydroxysteroid dehydrogenase activity and subsequent nongenomic estrogen signaling in human CRC tissue, in The Cancer Genome Atlas colon adenocarcinoma data set, and in in vitro and in vivo CRC models.
|
28945888 |
2017 |
|
Adenoma
|
0.010 |
Biomarker
|
group |
BEFREE |
Reversible 17betaHSD activity was found in 9 of 11 adenomas, and 17betaHSD type 1 immunopositivity was cytoplasmically distributed in all 6 adenomas in vitro.
|
10199776 |
1999 |
|
Adrenal Gland Pheochromocytoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of 17β-hydroxysteroid dehydrogenase type 10 increases pheochromocytoma cell growth and resistance to cell death.
|
25879199 |
2015 |
|
Alzheimer's Disease
|
0.090 |
Biomarker
|
disease |
BEFREE |
In vitro study of interaction of 17β-hydroxysteroid dehydrogenase type 10 and cyclophilin D and its potential implications for Alzheimer's disease.
|
31723183 |
2019 |
|
Alzheimer's Disease
|
0.090 |
Biomarker
|
disease |
BEFREE |
Moreover, our inverse docking results showed that curcumin potentially binds also to the proteins cAMP-specific 3',5'-cyclic phosphodiesterase 4D and 17-β-hydroxysteroid dehydrogenase type 10, which provides a new explanation for its efficiency in the treatment of Alzheimer's disease.
|
30567342 |
2018 |
|
Alzheimer's Disease
|
0.090 |
Biomarker
|
disease |
BEFREE |
<b>:</b> It has long been established that mitochondrial dysfunction in Alzheimer's disease (AD) patients can trigger pathological changes in cell metabolism by altering metabolic enzymes such as the mitochondrial 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10), also known as amyloid-binding alcohol dehydrogenase (ABAD).
|
31362457 |
2019 |
|
Alzheimer's Disease
|
0.090 |
Biomarker
|
disease |
BEFREE |
17β-Hydroxysteroid dehydrogenase type 10 (17β-HSD10) is a mitochondrial enzyme known for its potential role in Alzheimer's Disease (AD).
|
30297283 |
2018 |
|
Alzheimer's Disease
|
0.090 |
Biomarker
|
disease |
BEFREE |
The enzyme 17beta-hydroxysteroid dehydrogenase type 10 (HSD10), also known as amyloid beta-peptide-binding alcohol dehydrogenase (ABAD), has been implicated in the development of Alzheimer's disease.
|
15342248 |
2004 |
|
Alzheimer's Disease
|
0.090 |
Biomarker
|
disease |
BEFREE |
The multifunctional mitochondrial enzyme 17beta-hydroxysteroid dehydrogenase type 10 could play a role in the development of Alzheimer disease via its high-affinity binding to amyloid-beta peptides and its overexpression.
|
18765932 |
2008 |
|
Alzheimer's Disease
|
0.090 |
Biomarker
|
disease |
BEFREE |
The mitochondrial enzyme amyloid beta-binding alcohol dehydrogenase (ABAD) also known as 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10) has been connected with the pathogenesis of Alzheimer's disease (AD).
|
28067167 |
2017 |
|
Alzheimer's Disease
|
0.090 |
Biomarker
|
disease |
BEFREE |
Roles of Mitochondrial 17β-Hydroxysteroid Dehydrogenase Type 10 in Alzheimer's Disease.
|
29480196 |
2018 |
|
Alzheimer's Disease
|
0.090 |
Biomarker
|
disease |
BEFREE |
Abundant type 10 17 beta-hydroxysteroid dehydrogenase in the hippocampus of mouse Alzheimer's disease model.
|
11869808 |
2002 |
|
Ambiguous Genitalia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Steroid 17β-hydroxysteroid dehydrogenase III (17β-HSD3) deficiency is a rare autosomal recessive disorder that usually presents in patients with a 46,XY karyotype with ambiguous genitalia at birth.
|
25536660 |
2015 |
|
Androgen-Insensitivity Syndrome
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Gonadotropin-stimulated serum testosterone/androstenedione ratios in 17betaHSD3-deficient patients were discriminative in all cases and did not overlap with ratios in normal controls or with ratios in AIS patients.
|
10599740 |
1999 |
|
Benign Prostatic Hyperplasia
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
17beta-Hydroxysteroid dehydrogenase (17beta-HSD) types 1, 2, 4, 7, and 12, as well as aromatase mRNA and protein expressions, were studied in benign prostatic hyperplasia (BPH) specimens using in situ hybridization and immunohistochemistry.
|
16651392 |
2006 |
|
Benign Prostatic Hyperplasia
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Significantly higher expressions of 17HSD type 2 and 5alpha-reductase type 2 were detected in benign prostatic hyperplasia compared with the carcinoma specimens.
|
8608963 |
1996 |
|
Benign Prostatic Hyperplasia
|
0.030 |
Biomarker
|
disease |
BEFREE |
The aim of this study on testosterone (T) metabolism in benign prostatic hyperplasia (BPH) and prostatic cancer was to compare the formation of metabolites in freshly isolated epithelial cells and in cells of long-term cultures (2 passages) and to identify the 5alpha-reductase (5alpha-R) and 17beta-hydroxysteroid dehydrogenase (17beta-HSD) isoforms responsible for metabolite formation.
|
9506528 |
1998 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this report, we show high expression of HSD17B7 in human ductal carcinoma and breast cancer cell lines and present evidence for a strong up-regulation of this enzyme by estradiol at the level of mRNA, protein expression, and promoter activity in MCF-7 cells.
|
21372145 |
2011 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
17beta-hydroxysteroid dehydrogenase type 1 modulates breast cancer protein profile and impacts cell migration.
|
22691413 |
2012 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
17beta-hydroxysteroid dehydrogenase type 5 is negatively correlated to apoptosis inhibitor GRP78 and tumor-secreted protein PGK1, and modulates breast cancer cell viability and proliferation.
|
28457968 |
2017 |